The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
There is a need to improve early detection, monitoring of relapse, and treatments for melanoma, to increase long-term survival. My research vision is to use innovative and cutting edge approaches to conduct a range of complementary studies under three broad but inter-related themes: Theme 1 – Genetic predisposition to melanoma in the general population; Theme 2 – Genetic predisposition to melanoma in high-density families; Theme 3 – Somatic aberrations underlying melanoma development.
Characterising The Effects Of Oxidative Stress On The Human L-type Ca2+ Channel Isoforms And Role In Human Pathology
Funder
National Health and Medical Research Council
Funding Amount
$250,805.00
Summary
Oxidative stress, poor energy production and increases in intracellular calcium are features of the failing heart. I have determined that the function of the L-type calcium channel, the primary protein responsible for calcium influx and contraction can be regulated by free radicals produced by the mitochondria (powerhouse of the cell). This proposal will determine the site of modification on the human L-type calcium channel and how communication between the channel and the mitochondria is altere ....Oxidative stress, poor energy production and increases in intracellular calcium are features of the failing heart. I have determined that the function of the L-type calcium channel, the primary protein responsible for calcium influx and contraction can be regulated by free radicals produced by the mitochondria (powerhouse of the cell). This proposal will determine the site of modification on the human L-type calcium channel and how communication between the channel and the mitochondria is altered in animal models of human disease.Read moreRead less
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Cancer Genetics, Epigenetics And Targeted Therapies
Funder
National Health and Medical Research Council
Funding Amount
$873,684.00
Summary
I aim to gain greater insight into how blood cancers arise and how we should ultimately treat patients with these diseases. I will identify the genetic defects that underpin the development of blood cancers, how these genetic defects de-regulate gene expression through so-called “epigenetic” changes to allow these abnormal blood cells grow and survive. I will test the activity of small molecules that interfere with the cancer-causing epigenetic and signaling pathways in experimental models.
I lead a research program to improve outcomes for patients with chronic myeloid leukaemia (CML). We aim to identify poor risk patients and test new treatment strategies to reduce adverse outcomes. In good risk patients we aim to reduce the need for lifelong drug dependency. Through a combination of clinical trials, innovative correlative studies, and strong scientific collaborations, my team will continue to improve outcomes for CML patients globally.
The L-type Calcium Channel In Cardiovascular Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Calcium influx into cardiac muscle cells occurs via the L-type calcium channel. The channel is essential to life but when function is altered it can contribute to the development of sudden death and heart failure. I have made significant discoveries in understanding the role of the channel in disease and I have exploited this knowledge to design therapy including a novel class of calcium channel antagonists to prevent the development of heart failure.
Overcoming Resistance Of Human Metastatic Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$727,758.00
Summary
Melanoma is a major Australian health problem, but there is no curative treatment once the disease spreads beyond the skin. I have been working on “overcoming resistance of melanoma to treatment” continuously for 10 years. My past research has provided a number of insights into the resistance of melanoma to treatment. I wish to extend my work to find new treatment approaches against the disease. If successful, this work will greatly benefit melanoma patients and Australian people.
Developing New Therapeutic Strategies For Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Each year, over 1,500 Australians will develop brain cancer. Unlike many cancers, it cannot be prevented by lifestyle changes. Adults with brain cancer usually die within 2 years. The overall aims of this funding are to extend patients' lives and build brain cancer research in Australia so that we have the best chance of curing this disease. The expected outcome is clinical trial of drug candidates for the most common and most deadly brain cancer, high-grade glioma.
While most leukemia patients initially respond well to chemotherapy, >70% die because the disease returns as a result of the survival of leukaemia cells following treatment. We seek to block the switch mechanisms within leukemic cells that allow them to survive current drug therapies. We now seek to examine the therapeutic potential of our discovery with a view toward developing new targetted therapies in the future.